These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 31337258

  • 21. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
    Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.
    Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
    [Abstract] [Full Text] [Related]

  • 22. Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.
    Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L.
    Neuropharmacology; 2017 Oct; 125():39-49. PubMed ID: 28705439
    [Abstract] [Full Text] [Related]

  • 23. Nociceptin and the NOP receptor in aversive learning in mice.
    Adem A, Madjid N, Kahl U, Holst S, Sadek B, Sandin J, Terenius L, Ögren SO.
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1298-1307. PubMed ID: 29102248
    [Abstract] [Full Text] [Related]

  • 24. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM, Rutten K.
    Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
    [Abstract] [Full Text] [Related]

  • 25. Nociceptin/orphanin FQ and NOP receptor gene regulation after acute or repeated social defeat stress.
    Green MK, Devine DP.
    Neuropeptides; 2009 Dec; 43(6):507-14. PubMed ID: 19720395
    [Abstract] [Full Text] [Related]

  • 26. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.
    Gavioli EC, Calo' G.
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Feb; 372(5):319-30. PubMed ID: 16491387
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice.
    Medeiros IU, Ruzza C, Asth L, Guerrini R, Romão PR, Gavioli EC, Calo G.
    Peptides; 2015 Oct; 72():95-103. PubMed ID: 26028163
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
    Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G.
    J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
    Chiou LC, Fan SH, Chuang KC, Liao YY, Lee SZ.
    Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.